Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Therapy in Pediatric Renal Transplantation
NCT00000936Phase 3Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 1999
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of muromonab-CD3 in kidney transplant rejection (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: One-year graft function at 1 year and Efficacy of Sandimmune and Neoral with respect to graft function. Started Nov 1999; status: terminated.
02
Drugs
muromonab-CD3
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00000936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000936.